LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 67

Search options

  1. Article ; Online: Chronic hepatitis B virus infection deteriorates disease outcome of coronavirus disease 2019 in hamster.

    Yuan, Lunzhi / Liu, Xuan / Guan, Yi / Cheng, Tong / Xia, Ningshao

    MedComm

    2024  Volume 5, Issue 3, Page(s) e499

    Language English
    Publishing date 2024-02-28
    Publishing country China
    Document type Journal Article
    ISSN 2688-2663
    ISSN (online) 2688-2663
    DOI 10.1002/mco2.499
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1.

    Yuan, Lunzhi / Liu, Xuan / Li, Song / Zhong, Wu / Xia, Ningshao

    MedComm

    2024  Volume 5, Issue 3, Page(s) e500

    Language English
    Publishing date 2024-02-28
    Publishing country China
    Document type Journal Article
    ISSN 2688-2663
    ISSN (online) 2688-2663
    DOI 10.1002/mco2.500
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Animal models for emerging coronavirus: progress and new insights.

    Yuan, Lunzhi / Tang, Qiyi / Cheng, Tong / Xia, Ningshao

    Emerging microbes & infections

    2020  Volume 9, Issue 1, Page(s) 949–961

    Abstract: The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within ... ...

    Abstract The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (17 April 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases.
    MeSH term(s) Animals ; Betacoronavirus/physiology ; COVID-19 ; Coronaviridae Infections/pathology ; Coronaviridae Infections/prevention & control ; Coronavirus Infections/pathology ; Coronavirus Infections/prevention & control ; Disease Models, Animal ; Humans ; Middle East Respiratory Syndrome Coronavirus/physiology ; Pandemics/prevention & control ; Pneumonia, Viral/pathology ; Pneumonia, Viral/prevention & control ; Research/trends ; Severe acute respiratory syndrome-related coronavirus/physiology ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-04-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2681359-2
    ISSN 2222-1751 ; 2222-1751
    ISSN (online) 2222-1751
    ISSN 2222-1751
    DOI 10.1080/22221751.2020.1764871
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters.

    Yuan, Lunzhi / Zhou, Ming / Ma, Jian / Liu, Xuan / Chen, Peiwen / Zhu, Huachen / Tang, Qiyi / Cheng, Tong / Guan, Yi / Xia, Ningshao

    Cellular & molecular immunology

    2022  Volume 19, Issue 2, Page(s) 290–292

    MeSH term(s) Animals ; Anti-Inflammatory Agents/administration & dosage ; Antibodies, Viral/blood ; COVID-19/metabolism ; COVID-19/pathology ; COVID-19/virology ; Cricetinae ; Dexamethasone/administration & dosage ; Disease Models, Animal ; Injections, Intraperitoneal ; Lung/metabolism ; Lung/pathology ; Lung/virology ; Male ; Mesocricetus ; RNA, Viral/genetics ; RNA, Viral/metabolism ; SARS-CoV-2/genetics ; Treatment Outcome ; Virus Replication/drug effects ; COVID-19 Drug Treatment
    Chemical Substances Anti-Inflammatory Agents ; Antibodies, Viral ; RNA, Viral ; Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2022-01-05
    Publishing country China
    Document type Letter
    ZDB-ID 2435097-7
    ISSN 2042-0226 ; 1672-7681
    ISSN (online) 2042-0226
    ISSN 1672-7681
    DOI 10.1038/s41423-021-00793-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Individualized prevention of proton pump inhibitor related adverse events by risk stratification.

    Xia, Bin / He, Qiangsheng / Smith, Fang Gao / Gkoutos, V Georgios / Nirantharakumar, Krishnarajah / Kuo, Zi Chong / Wang, Danni / Feng, Qi / Cheung, Eddie C / Dai, Lunzhi / Huang, Junjie / Yu, Yuanyuan / Meng, Wenbo / Qin, Xiwen / Yuan, Jinqiu

    Nature communications

    2024  Volume 15, Issue 1, Page(s) 3591

    Abstract: Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts ... ...

    Abstract Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public.
    MeSH term(s) Proton Pump Inhibitors/adverse effects ; Proton Pump Inhibitors/therapeutic use ; Humans ; Risk Assessment ; Male ; Female ; Middle Aged ; China/epidemiology ; United Kingdom/epidemiology ; Aged ; Prospective Studies ; United States/epidemiology ; Adult ; Precision Medicine ; Renal Insufficiency, Chronic/chemically induced ; Myocardial Ischemia/chemically induced ; Myocardial Ischemia/epidemiology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Respiratory Tract Infections/epidemiology ; Diabetes Mellitus/chemically induced ; Diabetes Mellitus/epidemiology ; Risk Factors
    Chemical Substances Proton Pump Inhibitors
    Language English
    Publishing date 2024-04-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-024-48007-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Female sex hormone, progesterone, ameliorates the severity of SARS-CoV-2-caused pneumonia in the Syrian hamster model.

    Yuan, Lunzhi / Zhu, Huachen / Wu, Kun / Zhou, Ming / Ma, Jian / Chen, Rirong / Tang, Qiyi / Cheng, Tong / Guan, Yi / Xia, Ningshao

    Signal transduction and targeted therapy

    2022  Volume 7, Issue 1, Page(s) 47

    MeSH term(s) Animals ; Antiviral Agents/pharmacology ; Body Weight/drug effects ; COVID-19/drug therapy ; COVID-19/genetics ; COVID-19/immunology ; COVID-19/virology ; Cricetulus ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/genetics ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/virology ; Disease Models, Animal ; Gene Expression/drug effects ; Humans ; Interferon-gamma/genetics ; Interferon-gamma/immunology ; Interleukin-10/genetics ; Interleukin-10/immunology ; Interleukin-6/genetics ; Interleukin-6/immunology ; Lung/drug effects ; Lung/immunology ; Lung/virology ; Male ; Progesterone/pharmacology ; SARS-CoV-2/drug effects ; SARS-CoV-2/growth & development ; SARS-CoV-2/immunology ; Severity of Illness Index ; Tumor Necrosis Factor-alpha/genetics ; Tumor Necrosis Factor-alpha/immunology
    Chemical Substances Antiviral Agents ; Interleukin-6 ; Tumor Necrosis Factor-alpha ; Interleukin-10 (130068-27-8) ; Progesterone (4G7DS2Q64Y) ; Interferon-gamma (82115-62-6)
    Language English
    Publishing date 2022-02-14
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 2886872-9
    ISSN 2059-3635 ; 2095-9907
    ISSN (online) 2059-3635
    ISSN 2095-9907
    DOI 10.1038/s41392-021-00860-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Butyrate Protects against SARS-CoV-2-Induced Tissue Damage in Golden Hamsters.

    Yu, Huan / Yuan, Lunzhi / Yan, Zhigang / Zhou, Ming / Ye, Jianghui / Wu, Kun / Chen, Wenjia / Chen, Rirong / Xia, Ningshao / Guan, Yi / Zhu, Huachen

    International journal of molecular sciences

    2023  Volume 24, Issue 18

    Abstract: Butyrate, produced by gut microbe during dietary fiber fermentation, has anti-inflammatory and antioxidant effects on chronic inflammation diseases, yet it remains to be explored whether butyrate has protective effects against viral infections. Here, we ... ...

    Abstract Butyrate, produced by gut microbe during dietary fiber fermentation, has anti-inflammatory and antioxidant effects on chronic inflammation diseases, yet it remains to be explored whether butyrate has protective effects against viral infections. Here, we demonstrated that butyrate alleviated tissue injury in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected golden hamsters supplemented with butyrate before and during the infection. Butyrate-treated hamsters showed augmentation of type I interferon (IFN) response and activation of endothelial cells without exaggerated inflammation. In addition, butyrate regulated redox homeostasis by enhancing the activity of superoxide dismutase (SOD) to inhibit excessive apoptotic cell death. Therefore, butyrate exhibited effective prevention against SARS-CoV-2 by upregulating antiviral immune responses and promoting cell survival.
    Language English
    Publishing date 2023-09-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms241814191
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.

    Ma, Jian / Liu, Xuan / Zhou, Ming / Chen, Peiwen / Chen, Rirong / Wang, Jia / Zhu, Huachen / Wu, Kun / Ye, Jianghui / Zhang, Yali / Yuan, Quan / Tang, Qiyi / Yuan, Lunzhi / Cheng, Tong / Guan, Yi / Xia, Ningshao

    Journal of virology

    2023  Volume 97, Issue 2, Page(s) e0168422

    Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is becoming a dominant circulator and has several mutations in the spike glycoprotein, which may cause shifts of immunogenicity, so as to result in immune escape and ... ...

    Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is becoming a dominant circulator and has several mutations in the spike glycoprotein, which may cause shifts of immunogenicity, so as to result in immune escape and breakthrough infection among the already infected or vaccinated populations. It is unclear whether infection with Omicron could generate adequate cross-variant protection. To investigate this possibility, we used Syrian hamsters as an animal model for infection of SARS-CoV-2. The serum from Omicron BA.1 variant-infected hamsters showed a significantly lower neutralization effect against infection of the same or different SARS-CoV-2 variants than the serum from Beta variant-infected hamsters. Furthermore, the serum from Omicron BA.1 variant-infected hamsters were insufficient to protect against rechallenge of SARS-CoV-2 Prototype, Beta and Delta variants and itself. Importantly, we found that rechallenge with different SARS-CoV-2 lineages elevated cross-variant serum neutralization titers. Overall, our findings indicate a weakened immunogenicity feature of Omicron BA.1 variant that can be overcome by rechallenge of a different SARS-CoV-2 lineages. Our results may lead to a new guideline in generation and use of the vaccinations to combat the pandemic of SARS-CoV-2 Omicron variant and possible new variants.
    MeSH term(s) Animals ; Cricetinae ; Antibodies, Neutralizing ; Antibodies, Viral ; Antigens, Heterophile/immunology ; Breakthrough Infections ; COVID-19/prevention & control ; Mesocricetus ; SARS-CoV-2/genetics ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/genetics ; Immunogenicity, Vaccine
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Antigens, Heterophile ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
    Language English
    Publishing date 2023-01-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80174-4
    ISSN 1098-5514 ; 0022-538X
    ISSN (online) 1098-5514
    ISSN 0022-538X
    DOI 10.1128/jvi.01684-22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications.

    Yuan, Lunzhi / Tang, Qiyi / Zhu, Huachen / Guan, Yi / Cheng, Tong / Xia, Ningshao

    Emerging microbes & infections

    2021  Volume 10, Issue 1, Page(s) 1881–1889

    Abstract: SARS-CoV-2 has been the causative pathogen of the pandemic of COVID-19, resulting in catastrophic health issues globally. It is important to develop human-like animal models for investigating the mechanisms that SARS-CoV-2 uses to infect humans and cause ...

    Abstract SARS-CoV-2 has been the causative pathogen of the pandemic of COVID-19, resulting in catastrophic health issues globally. It is important to develop human-like animal models for investigating the mechanisms that SARS-CoV-2 uses to infect humans and cause COVID-19. Several studies demonstrated that the non-human primate (NHP) is permissive for SARS-CoV-2 infection to cause typical clinical symptoms including fever, cough, breathing difficulty, and other diagnostic abnormalities such as immunopathogenesis and hyperplastic lesions in the lung. These NHP models have been used for investigating the potential infection route and host immune response to SARS-CoV-2, as well as testing vaccines and drugs. This review aims to summarize the benefits and caveats of NHP models currently available for SARS-CoV-2, and to discuss key topics including model optimization, extended application, and clinical translation.
    MeSH term(s) Animals ; Antiviral Agents/administration & dosage ; COVID-19/immunology ; COVID-19/pathology ; COVID-19/virology ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/immunology ; Disease Models, Animal ; Humans ; Primates/immunology ; Primates/virology ; SARS-CoV-2/genetics ; SARS-CoV-2/physiology ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents ; COVID-19 Vaccines
    Language English
    Publishing date 2021-08-19
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2681359-2
    ISSN 2222-1751 ; 2222-1751
    ISSN (online) 2222-1751
    ISSN 2222-1751
    DOI 10.1080/22221751.2021.1976598
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: TBC1D23 mediates Golgi-specific LKB1 signaling.

    Tu, Yingfeng / Yang, Qin / Tang, Min / Gao, Li / Wang, Yuanhao / Wang, Jiuqiang / Liu, Zhe / Li, Xiaoyu / Mao, Lejiao / Jia, Rui Zhen / Wang, Yuan / Tang, Tie-Shan / Xu, Pinglong / Liu, Yan / Dai, Lunzhi / Jia, Da

    Nature communications

    2024  Volume 15, Issue 1, Page(s) 1785

    Abstract: Liver kinase B1 (LKB1), an evolutionarily conserved serine/threonine kinase, is a master regulator of the AMPK subfamily and controls cellular events such as polarity, proliferation, and energy homeostasis. Functions and mechanisms of the LKB1-AMPK axis ... ...

    Abstract Liver kinase B1 (LKB1), an evolutionarily conserved serine/threonine kinase, is a master regulator of the AMPK subfamily and controls cellular events such as polarity, proliferation, and energy homeostasis. Functions and mechanisms of the LKB1-AMPK axis at specific subcellular compartments, such as lysosome and mitochondria, have been established. AMPK is known to be activated at the Golgi; however, functions and regulatory mechanisms of the LKB1-AMPK axis at the Golgi apparatus remain elusive. Here, we show that TBC1D23, a Golgi-localized protein that is frequently mutated in the neurodevelopment disorder pontocerebellar hypoplasia (PCH), is specifically required for the LKB1 signaling at the Golgi. TBC1D23 directly interacts with LKB1 and recruits LKB1 to Golgi, promoting Golgi-specific activation of AMPK upon energy stress. Notably, Golgi-targeted expression of LKB1 rescues TBC1D23 deficiency in zebrafish models. Furthermore, the loss of LKB1 causes neurodevelopmental abnormalities in zebrafish, which partially recapitulates defects in TBC1D23-deficient zebrafish, and LKB1 sustains normal neuronal development via TBC1D23 interaction. Our study uncovers a regulatory mechanism of the LKB1 signaling, and reveals that a disrupted Golgi-LKB1 signaling underlies the pathogenesis of PCH.
    MeSH term(s) Animals ; Zebrafish/metabolism ; AMP-Activated Protein Kinases/metabolism ; Protein Serine-Threonine Kinases/genetics ; Protein Serine-Threonine Kinases/metabolism ; Signal Transduction ; Golgi Apparatus/metabolism ; Cerebellar Diseases
    Chemical Substances AMP-Activated Protein Kinases (EC 2.7.11.31) ; Protein Serine-Threonine Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2024-02-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-024-46166-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top